Company Filing History:
Years Active: 2016
Title: Mark B Nolt: Innovator in Therapeutic Agents for CNS Disorders
Introduction
Mark B Nolt is a distinguished inventor based in Lansdale, PA (US). He has made significant contributions to the field of therapeutic agents, particularly in the treatment of central nervous system disorders. His innovative work has the potential to impact the lives of many individuals suffering from various neurological and psychiatric conditions.
Latest Patents
Mark B Nolt holds a patent for "Triazolopyridinone PDE10 inhibitors." This invention is directed towards triazolopyridinone compounds that serve as therapeutic agents for treating central nervous system disorders associated with phosphodiesterase 10 (PDE10). The compounds are particularly useful for addressing neurological and psychiatric disorders such as schizophrenia, psychosis, and Huntington's disease, as well as conditions related to striatal hypofunction or basal ganglia dysfunction. He has 1 patent to his name.
Career Highlights
Mark B Nolt is currently employed at Merck Sharp & Dohme Corporation, where he continues to advance his research and development efforts. His work at this prominent pharmaceutical company allows him to collaborate with other leading experts in the field.
Collaborations
Some of his notable coworkers include James C Barrow and Christopher D Cox. Their collective expertise contributes to the innovative environment at Merck Sharp & Dohme Corporation.
Conclusion
Mark B Nolt is a key figure in the development of therapeutic agents for central nervous system disorders. His patent on triazolopyridinone PDE10 inhibitors showcases his commitment to improving treatment options for patients. His work continues to inspire advancements in the field of neuroscience.